{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:19:08Z","timestamp":1790893148990,"version":"4.1.0"},"reference-count":187,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019624","name":"University Hospital Hradec Kralove","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019624","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007543","name":"Grantov\u00e1 Agentura, Univerzita Karlova","doi-asserted-by":"publisher","award":["SVV 260 547"],"award-info":[{"award-number":["SVV 260 547"]}],"id":[{"id":"10.13039\/100007543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health of the Czech Republic","doi-asserted-by":"publisher","award":["NU21-05-00446"],"award-info":[{"award-number":["NU21-05-00446"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007397","name":"Charles University","doi-asserted-by":"publisher","award":["392822"],"award-info":[{"award-number":["392822"]}],"id":[{"id":"10.13039\/100007397","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.apsb.2025.01.023","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T20:02:43Z","timestamp":1738267363000},"page":"1311-1332","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6254-6485","authenticated-orcid":false,"given":"Martin","family":"Kufa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Finger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Kovar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6376-8701","authenticated-orcid":false,"given":"Ondrej","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9858-8572","authenticated-orcid":false,"given":"Carilyn","family":"Torruellas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4698-8379","authenticated-orcid":false,"given":"Jaroslav","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-7596","authenticated-orcid":false,"given":"Jan","family":"Korabecny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.01.023_bib2","unstructured":"The top 10 causes of death. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/the-top-10-causes-of-death (accessed 2022-May-16)."},{"key":"10.1016\/j.apsb.2025.01.023_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: a systematic review and meta-analysis","volume":"54","author":"Cohen","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.apsb.2025.01.023_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0017601","article-title":"Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review","volume":"6","author":"Tiemersma","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2025.01.023_bib6","article-title":"Factors predictive of the success of tuberculosis treatment: a systematic review with meta-analysis","volume":"14","author":"Torres","year":"2019","journal-title":"PLOS ONE"},{"key":"10.1016\/j.apsb.2025.01.023_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.625078","article-title":"Adherence and associated factors of treatment regimen in drug-susceptible tuberculosis patients","volume":"12","author":"Bea","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2025.01.023_bib9","doi-asserted-by":"crossref","first-page":"e93","DOI":"10.1164\/rccm.201909-1874ST","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2025.01.023_bib11","unstructured":"WHO consolidated guidelines on drug-resistant tuberculosis treatment. Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789241550529 (accessed 2023-April-5)."},{"key":"10.1016\/j.apsb.2025.01.023_bib12","unstructured":"2022 Report on TB Research Funding Trends. Treatment Action Group. Available from: https:\/\/www.treatmentactiongroup.org\/resources\/tbrd-report\/tbrd-report-2022\/(accessed 2023-April-6)."},{"key":"10.1016\/j.apsb.2025.01.023_bib13","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.01.023_bib14","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1007\/s40265-014-0241-5","article-title":"Delamanid: first global approval","volume":"74","author":"Ryan","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.01.023_bib15","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","article-title":"Pretomanid: first approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.01.023_bib16","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkaa136","article-title":"Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid","volume":"75","author":"Kadura","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib17","doi-asserted-by":"crossref","first-page":"10583","DOI":"10.1021\/acs.jmedchem.9b01716","article-title":"Changing the rules of TB-drug discovery","volume":"62","author":"Harrison","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-12718-4","article-title":"Dissecting the mycobacterial cell envelope and defining the composition of the native mycomembrane","volume":"7","author":"Chiaradia","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2025.01.023_bib19","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1021\/acsinfecdis.7b00255","article-title":"The expanding diversity of Mycobacterium tuberculosis drug targets","volume":"4","author":"Wellington","year":"2018","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2025.01.023_bib20","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S1473-3099(18)30110-5","article-title":"Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies","volume":"18","author":"Tiberi","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.apsb.2025.01.023_bib21","article-title":"The pipeline of new molecules and regimens against drug-resistant tuberculosis","volume":"25","author":"Black","year":"2021","journal-title":"J Clin Tuberc Other Mycobact Dis"},{"key":"10.1016\/j.apsb.2025.01.023_bib22","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-022-00731-y","article-title":"Anti-tuberculosis treatment strategies and drug development: challenges and priorities","volume":"20","author":"Dartois","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2025.01.023_bib23","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.trsl.2020.03.007","article-title":"New tuberculosis drug targets, their inhibitors, and potential therapeutic impact","volume":"220","author":"Shetye","year":"2020","journal-title":"Transl Res"},{"key":"10.1016\/j.apsb.2025.01.023_bib24","doi-asserted-by":"crossref","first-page":"5202","DOI":"10.3390\/ijms24065202","article-title":"Tuberculosis: pathogenesis, current treatment regimens and new drug targets","volume":"24","author":"Alsayed","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.01.023_bib25","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1111\/j.1365-2958.2006.05467.x","article-title":"Mechanisms of action of isoniazid","volume":"62","author":"Timmins","year":"2006","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.apsb.2025.01.023_bib26","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1126\/science.aba9102","article-title":"Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.01.023_bib27","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.biopha.2017.09.036","article-title":"Cell wall: a versatile fountain of drug targets in Mycobacterium tuberculosis","volume":"95","author":"Bhat","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2025.01.023_bib28","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00472-12","article-title":"Critical roles for lipomannan and lipoarabinomannan in cell wall integrity of Mycobacteria and pathogenesis of tuberculosis","volume":"4","author":"Fukuda","year":"2013","journal-title":"mBio"},{"key":"10.1016\/j.apsb.2025.01.023_bib29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nrmicro840","article-title":"Interplay between Mycobacteria and host signalling pathways","volume":"2","author":"Koul","year":"2004","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2025.01.023_bib30","doi-asserted-by":"crossref","first-page":"11998","DOI":"10.1021\/bi701506h","article-title":"Irreversible inhibition of the Mycobacterium tuberculosis \u03b2-lactamase by clavulanate","volume":"46","author":"Hugonnet","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.apsb.2025.01.023_bib31","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1128\/AAC.01957-12","article-title":"Involvement of efflux pumps in the resistance to peptidoglycan synthesis inhibitors in Mycobacterium tuberculosis","volume":"57","author":"Dinesh","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.bi.64.070195.000333","article-title":"The envelope of Mycobacteria","volume":"64","author":"Brennan","year":"1995","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.apsb.2025.01.023_bib33","doi-asserted-by":"crossref","first-page":"4958","DOI":"10.1073\/pnas.1403078111","article-title":"Mycobacterial outer membrane is a lipid bilayer and the inner membrane is unusually rich in diacyl phosphatidylinositol dimannosides","volume":"111","author":"Bansal-Mutalik","year":"2014","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2025.01.023_bib34","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3389\/fmicb.2018.00514","article-title":"Stable regulation of cell cycle events in Mycobacteria: insights from inherently heterogeneous bacterial populations","volume":"9","author":"Logsdon","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.apsb.2025.01.023_bib35","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1183\/09031936.00124312","article-title":"Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-\/XDR-TB","volume":"41","author":"De Lorenzo","year":"2013","journal-title":"Eur Respir J"},{"key":"10.1016\/j.apsb.2025.01.023_bib36","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1128\/AAC.00665-12","article-title":"Inactivation of Mycobacterium tuberculosis L,D-transpeptidase LdtMt1 by carbapenems and cephalosporins","volume":"56","author":"Dub\u00e9e","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib37","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.chembiol.2021.03.008","article-title":"N-Thio-\u03b2-lactams targeting L,D-transpeptidase-2, with activity against drug-resistant strains of Mycobacterium tuberculosis","volume":"28","author":"Martelli","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.apsb.2025.01.023_bib38","doi-asserted-by":"crossref","first-page":"5940","DOI":"10.1128\/AAC.01663-13","article-title":"In\u00a0vitro cross-linking of Mycobacterium tuberculosis peptidoglycan by L,D-transpeptidases and inactivation of these enzymes by carbapenems","volume":"57","author":"Cordillot","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib39","unstructured":"WHO consolidated guidelines on tuberculosis, module 4: treatment - drug-resistant tuberculosis treatment. Available from: https:\/\/www.who.int\/publications-detail-redirect\/9789240007048 (accessed 2022-May-26)."},{"key":"10.1016\/j.apsb.2025.01.023_bib40","unstructured":"Pipeline. Working group for new TB drugs. Available from: https:\/\/www.newtbdrugs.org\/pipeline\/clinical (accessed 2022-May-30)."},{"key":"10.1016\/j.apsb.2025.01.023_bib41","article-title":"Sanfetrinem or a salt or ester thereof for use in treating mycobacterial infection","author":"Aguirre","year":"2018","journal-title":"WO2018206466A1"},{"key":"10.1016\/j.apsb.2025.01.023_bib42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1099\/00221287-146-2-289","article-title":"InhA, a target of the antituberculous drug isoniazid, is involved in a mycobacterial fatty acid elongation system, FAS-II","volume":"146","author":"Marrakchi","year":"2000","journal-title":"Microbiology"},{"key":"10.1016\/j.apsb.2025.01.023_bib43","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1084\/jem.20062100","article-title":"Mechanism of thioamide drug action against tuberculosis and leprosy","volume":"204","author":"Wang","year":"2007","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2025.01.023_bib44","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1021\/ja950998b","article-title":"Binding of catalase-peroxidase-activated isoniazid to wild-type and mutant Mycobacterium tuberculosis enoyl-ACP reductases","volume":"118","author":"Quemard","year":"1996","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2025.01.023_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00616-19","article-title":"Bacterial genome-wide association identifies novel factors that contribute to ethionamide and prothionamide susceptibility in Mycobacterium tuberculosis","volume":"10","author":"Hicks","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.apsb.2025.01.023_bib46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1128\/microbiolspec.MGM2-0014-2013","article-title":"Resistance to isoniazid and ethionamide in Mycobacterium tuberculosis: genes, mutations, and causalities","volume":"2","author":"Vilch\u00e8ze","year":"2014","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.apsb.2025.01.023_bib47","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1183\/13993003.00438-2016","article-title":"Efficacy and tolerability of ethionamide versus prothionamide: a systematic review","volume":"48","author":"Scardigli","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.apsb.2025.01.023_bib48","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.drudis.2020.11.026","article-title":"Desirable drug\u2013drug interactions or when a matter of concern becomes a renewed therapeutic strategy","volume":"26","author":"Guieu","year":"2021","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2025.01.023_bib49","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1126\/science.aag1006","article-title":"Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420","volume":"355","author":"Blondiaux","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.01.023_bib50","author":"Porras De Francisco"},{"key":"10.1016\/j.apsb.2025.01.023_bib51","author":"Willand"},{"key":"10.1016\/j.apsb.2025.01.023_bib52","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13065-018-0441-2","article-title":"Decaprenyl-phosphoryl-ribose 2\u02b9-epimerase (DprE1): challenging target for antitubercular drug discovery","volume":"12","author":"Gawad","year":"2018","journal-title":"Chem Cent J"},{"key":"10.1016\/j.apsb.2025.01.023_bib53","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.drudis.2016.09.014","article-title":"Structural studies of Mycobacterium tuberculosis DprE1 interacting with its inhibitors","volume":"22","author":"Piton","year":"2017","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.apsb.2025.01.023_bib54","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.3390\/app10072269","article-title":"Development of macozinone for TB treatment: an update","volume":"10","author":"Makarov","year":"2020","journal-title":"Appl Sci"},{"key":"10.1016\/j.apsb.2025.01.023_bib55","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/emmm.201303575","article-title":"Towards a new combination therapy for tuberculosis with next generation benzothiazinones","volume":"6","author":"Makarov","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.apsb.2025.01.023_bib56","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.1171583","article-title":"Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis","volume":"324","author":"Makarov","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.01.023_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31316-6","article-title":"Novel insight into the reaction of nitro, nitroso and hydroxylamino benzothiazinones and of benzoxacinones with Mycobacterium tuberculosis DprE1","volume":"8","author":"Richter","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2025.01.023_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115545","article-title":"Design, synthesis and antitubercular activity of novel N-(amino)piperazinyl benzothiazinones with improved safety","volume":"258","author":"Wang","year":"2023","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib59","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.bmcl.2013.06.069","article-title":"Synthesis and structure\u2012activity relationships evaluation of benzothiazinone derivatives as potential anti-tubercular agents","volume":"23","author":"Gao","year":"2013","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2025.01.023_bib60","doi-asserted-by":"crossref","first-page":"9701","DOI":"10.1021\/jm401382v","article-title":"Azaindoles: noncovalent DprE1 inhibitors from scaffold morphing efforts, kill Mycobacterium tuberculosis and are efficacious in\u00a0vivo","volume":"56","author":"Shirude","year":"2013","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib61","doi-asserted-by":"crossref","first-page":"8563","DOI":"10.1021\/acs.jmedchem.8b00281","article-title":"Overview of the development of DprE1 inhibitors for combating the menace of tuberculosis","volume":"61","author":"Chikhale","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib62","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02020-19","article-title":"OPC-167832, a novel carbostyril derivative with potent antituberculosis activity as a DprE1 inhibitor","volume":"64","author":"Hariguchi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib63","author":"Shimizu"},{"key":"10.1016\/j.apsb.2025.01.023_bib64","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.03233-14","article-title":"1,4-Azaindole, a potential drug candidate for treatment of tuberculosis","volume":"58","author":"Chatterji","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib65","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1021\/jm500571f","article-title":"Lead optimization of 1,4-azaindoles as antimycobacterial agents","volume":"57","author":"Shirude","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib66","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1021\/jm500571f","article-title":"Lead optimization of 1,4-Azaindoles as antimycobacterial agents","volume":"57","author":"Shirude","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib67","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.1038\/s41467-023-39300-z","article-title":"DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid","volume":"14","author":"Abrahams","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.01.023_bib68","doi-asserted-by":"crossref","first-page":"11241","DOI":"10.1073\/pnas.1901346116","article-title":"MmpL3 is a lipid transporter that binds trehalose monomycolate and phosphatidylethanolamine","volume":"116","author":"Su","year":"2019","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2025.01.023_bib69","doi-asserted-by":"crossref","DOI":"10.1038\/srep43495","article-title":"Essentiality of mmpL3 and impact of its silencing on Mycobacterium tuberculosis gene expression","volume":"7","author":"Degiacomi","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2025.01.023_bib70","doi-asserted-by":"crossref","first-page":"5051","DOI":"10.1073\/pnas.1009516108","article-title":"Discovery and characterization of a unique mycobacterial heme acquisition system","volume":"108","author":"Tullius","year":"2011","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2025.01.023_bib71","doi-asserted-by":"crossref","first-page":"5305","DOI":"10.1128\/IAI.69.9.5305-5312.2001","article-title":"Role of trehalose dimycolate in recruitment of cells and modulation of production of cytokines and NO in tuberculosis","volume":"69","author":"Lima","year":"2001","journal-title":"Infect Immun"},{"key":"10.1016\/j.apsb.2025.01.023_bib72","doi-asserted-by":"crossref","first-page":"5198","DOI":"10.1128\/AAC.00826-16","article-title":"Therapeutic potential of the Mycobacterium tuberculosis mycolic acid transporter, MmpL3","volume":"60","author":"Li","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib73","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/jac\/dki319","article-title":"Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines","volume":"56","author":"Protopopova","year":"2005","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib74","doi-asserted-by":"crossref","first-page":"6413","DOI":"10.1128\/AAC.03229-14","article-title":"Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib75","doi-asserted-by":"crossref","DOI":"10.1099\/acmi.0.000006","article-title":"Cell wall inhibitors increase the accumulation of rifampicin in Mycobacterium tuberculosis","volume":"1","author":"McNeil","year":"2019","journal-title":"Access Microbiol"},{"key":"10.1016\/j.apsb.2025.01.023_bib76","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1093\/jac\/dkl227","article-title":"Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in\u00a0vitro","volume":"58","author":"Chen","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib77","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.1128\/AAC.01601-09","article-title":"In\u00a0vitro interactions between new antitubercular drug candidates SQ109 and TMC207","volume":"54","author":"Reddy","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib78","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2217\/fmb.12.56","article-title":"Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action","volume":"7","author":"Sacksteder","year":"2012","journal-title":"Future Microbiol"},{"key":"10.1016\/j.apsb.2025.01.023_bib79","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.cell.2019.01.003","article-title":"Crystal structures of membrane transporter MmpL3, an anti-TB drug target","volume":"176","author":"Zhang","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.01.023_bib80","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1021\/jm500131s","article-title":"Multitarget drug discovery for tuberculosis and other infectious diseases","volume":"57","author":"Li","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib81","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1128\/mr.59.1.48-62.1995","article-title":"Energetics of bacterial growth: balance of anabolic and catabolic reactions","volume":"59","author":"Russell","year":"1995","journal-title":"Microbiol Rev"},{"key":"10.1016\/j.apsb.2025.01.023_bib82","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2120352119","article-title":"50S S subunit recognition and modification by the Mycobacterium tuberculosis ribosomal RNA methyltransferase TlyA","volume":"119","author":"Laughlin","year":"2022","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.apsb.2025.01.023_bib83","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pbiomolbio.2019.12.001","article-title":"Unique structural features of the Mycobacterium ribosome","volume":"152","author":"Kushwaha","year":"2020","journal-title":"Prog Biophys Mol Biol"},{"key":"10.1016\/j.apsb.2025.01.023_bib84","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.celrep.2017.06.029","article-title":"The complete structure of the Mycobacterium smegmatis 70S S ribosome","volume":"20","author":"Hentschel","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2025.01.023_bib85","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1089\/107662902760190707","article-title":"Investigation of the in\u00a0vitro activity of streptomycin against Mycobacterium tuberculosis","volume":"8","author":"Ruiz","year":"2002","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.apsb.2025.01.023_bib86","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1093\/emboj\/18.11.3133","article-title":"Basis for prokaryotic specificity of action of aminoglycoside antibiotics","volume":"18","author":"Recht","year":"1999","journal-title":"EMBO J"},{"key":"10.1016\/j.apsb.2025.01.023_bib87","doi-asserted-by":"crossref","first-page":"19192","DOI":"10.1039\/C9CP03631H","article-title":"Binding energies of the drugs capreomycin and streptomycin in complex with tuberculosis bacterial ribosome subunits","volume":"21","author":"Vianna","year":"2019","journal-title":"Phys Chem Chem Phys"},{"key":"10.1016\/j.apsb.2025.01.023_bib88","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jac\/dkw450","article-title":"Linezolid: a promising option in the treatment of Gram-positives","volume":"72","author":"Zahedi Bialvaei","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib89","doi-asserted-by":"crossref","first-page":"S407","DOI":"10.1093\/clinids\/5.Supplement_3.S407","article-title":"Rifampin: mechanisms of action and resistance","volume":"5","author":"Wehrli","year":"1983","journal-title":"Rev Infect Dis"},{"key":"10.1016\/j.apsb.2025.01.023_bib90","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02586-16","article-title":"Adverse effects and choice between the injectable agents amikacin and capreomycin in multidrug-resistant tuberculosis","volume":"61","author":"Arnold","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib91","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00974-21","article-title":"In\u00a0vitro and in\u00a0vivo activity of oxazolidinone candidate OTB-658 against Mycobacterium tuberculosis","volume":"65","author":"Guo","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib92","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1128\/AAC.02941-15","article-title":"Mycobacterium tuberculosis mutations associated with reduced susceptibility to linezolid","volume":"60","author":"Zhang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib93","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1186\/2047-783X-15-12-554","article-title":"Treatment of complicated skin and soft-tissue infections caused by resistant bacteria: value of linezolid, tigecycline, daptomycin and vancomycin","volume":"15","author":"Eckmann","year":"2010","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.apsb.2025.01.023_bib94","doi-asserted-by":"crossref","first-page":"10557","DOI":"10.1021\/acs.jmedchem.1c00480","article-title":"Current landscape and future perspective of oxazolidinone scaffolds containing antibacterial drugs","volume":"64","author":"Zhao","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib95","doi-asserted-by":"crossref","DOI":"10.1002\/asia.202200201","article-title":"Strategies to improve the potency of oxazolidinones towards bacterial biofilms","volume":"17","author":"Ndukwe","year":"2022","journal-title":"Chem Asian J"},{"key":"10.1016\/j.apsb.2025.01.023_bib96","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1039\/D2MD00415A","article-title":"Oxazolidinones as versatile scaffolds in medicinal chemistry","volume":"14","author":"Fernandes","year":"2023","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib97","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.3390\/molecules26144280","article-title":"Oxazolidinone antibiotics: chemical, biological and analytical aspects","volume":"26","author":"Foti","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2025.01.023_bib98","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1128\/AAC.03684-14","article-title":"Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function","volume":"59","author":"Flanagan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib99","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01655-22","article-title":"Side-by-side profiling of oxazolidinones to estimate the therapeutic window against mycobacterial infections","volume":"67","author":"Negatu","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib100","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1128\/AAC.01411-05","article-title":"Inhibition of mammalian mitochondrial protein synthesis by oxazolidinones","volume":"50","author":"McKee","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib101","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ejmech.2014.08.066","article-title":"SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development","volume":"86","author":"Poce","year":"2014","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib102","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.2174\/0929867323666151106125759","article-title":"Oxazolidinones as anti-tubercular agents: discovery, development and future perspectives","volume":"22","author":"Jadhavar","year":"2015","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib103","doi-asserted-by":"crossref","first-page":"9316","DOI":"10.1021\/acs.jmedchem.0c00500","article-title":"Discovery of a conformationally constrained oxazolidinone with improved safety and efficacy profiles for the treatment of multidrug-resistant tuberculosis","volume":"63","author":"Zhao","year":"2020","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib104","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1128\/AAC.01179-10","article-title":"Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis","volume":"55","author":"Wallis","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib105","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00165-18","article-title":"Comparison of In\u00a0vitro activity and MIC distributions between the novel oxazolidinone delpazolid and linezolid against multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis in China","volume":"62","author":"Zong","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib106","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1093\/jac\/dkx367","article-title":"Safety, tolerability and pharmacokinetics of 21 day multiple oral administration of a new oxazolidinone antibiotic, LCB01-0371, in healthy male subjects","volume":"73","author":"Choi","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib107","unstructured":"TBI-223: a safer oxazolidinone in pre-clinical development for tuberculosis. Available from:: https:\/\/www.abstractsonline.com\/pp8\/#!\/4358\/presentation\/6174 (accessed 2022-August-10)."},{"key":"10.1016\/j.apsb.2025.01.023_bib108","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01939-18","article-title":"In\u00a0vitro activity of tedizolid against Mycobacterium tuberculosis","volume":"63","author":"Ruiz","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib109","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nm.3458","article-title":"Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux","volume":"20","author":"Lee","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2025.01.023_bib110","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1021\/acsinfecdis.6b00158","article-title":"Structure\u2013activity relationships of spectinamide antituberculosis agents: a dissection of ribosomal inhibition and native efflux avoidance contributions","volume":"3","author":"Liu","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2025.01.023_bib111","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41429-019-0194-8","article-title":"Aminomethyl spectinomycins: a novel antibacterial chemotype for biothreat pathogens","volume":"72","author":"Scarff","year":"2019","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.apsb.2025.01.023_bib112","first-page":"770","article-title":"Spectinamides are effective partner agents for the treatment of tuberculosis in multiple mouse infection models","volume":"72","author":"Robertson","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib113","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01744-20","article-title":"Model-based exposure-response assessment for spectinamide 1810 in a mouse model of tuberculosis","volume":"65","author":"Wagh","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib114","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00240-19","article-title":"First-time-in-human study and prediction of early bactericidal activity for GSK3036656, a potent leucyl-tRNA synthetase inhibitor for tuberculosis treatment","volume":"63","author":"Tenero","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib115","doi-asserted-by":"crossref","first-page":"6271","DOI":"10.1128\/AAC.01339-16","article-title":"Discovery of novel oral protein synthesis inhibitors of Mycobacterium tuberculosis that target leucyl-tRNA synthetase","volume":"60","author":"Palencia","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib116","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1021\/acs.jmedchem.7b00631","article-title":"Discovery of a potent and specific M. tuberculosis leucyl-tRNA synthetase inhibitor: (S)-3-(aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656)","volume":"60","author":"Li","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib117","author":"Alley"},{"key":"10.1016\/j.apsb.2025.01.023_bib118","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TBTB2-0014-2016","article-title":"Oxidative phosphorylation as a target space for tuberculosis: success, caution, and future directions","volume":"5","author":"Cook","year":"2017","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.apsb.2025.01.023_bib119","article-title":"Energetics of respiration and oxidative phosphorylation in Mycobacteria","volume":"3","author":"Cook","year":"2014","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.apsb.2025.01.023_bib120","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00272-17","article-title":"Targeting energy metabolism in Mycobacterium tuberculosis, a new paradigm in antimycobacterial drug discovery","volume":"8","author":"Bald","year":"2017","journal-title":"mBio"},{"key":"10.1016\/j.apsb.2025.01.023_bib121","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.medmal.2016.04.007","article-title":"In\u00a0vitro culture conditions affecting minimal inhibitory concentration of bedaquiline against","volume":"460","author":"Lounis","year":"2016","journal-title":"M Tuberculosis Med Mal Infect"},{"key":"10.1016\/j.apsb.2025.01.023_bib122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/2229-516X.112228","article-title":"Bedaquiline: first FDA-approved tuberculosis drug in 40 years","volume":"3","author":"Mahajan","year":"2013","journal-title":"Int J Appl Basic Med Res"},{"key":"10.1016\/j.apsb.2025.01.023_bib123","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1016\/j.bmc.2019.02.026","article-title":"3,5-Dialkoxypyridine analogues of bedaquiline are potent antituberculosis agents with minimal inhibition of the hERG channel","volume":"27","author":"Sutherland","year":"2019","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib124","article-title":"Whole genome sequencing identifies novel mutations associated with bedaquiline resistance in Mycobacterium tuberculosis","volume":"12","author":"Guo","year":"2022","journal-title":"Front Cel Infect Microbiol"},{"key":"10.1016\/j.apsb.2025.01.023_bib125","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00292-19","article-title":"In\u00a0vitro study of stepwise acquisition of Rv0678 and atpE mutations conferring bedaquiline resistance","volume":"63","author":"Ismail","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2019.115213","article-title":"Variations in the C-unit of bedaquiline provides analogues with improved biology and pharmacology","volume":"28","author":"Sutherland","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib127","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40121-013-0009-3","article-title":"A review of the evidence for using bedaquiline (TMC207) to treat multi-drug resistant tuberculosis","volume":"2","author":"Fox","year":"2013","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.apsb.2025.01.023_bib128","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1021\/acsmedchemlett.7b00196","article-title":"6-Cyano analogues of bedaquiline as less lipophilic and potentially safer diarylquinolines for tuberculosis","volume":"8","author":"Tong","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2025.01.023_bib129","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.4155\/fmc.11.79","article-title":"Diarylquinolines, synthesis pathways and quantitative structure\u2012activity relationship studies leading to the discovery of TMC207","volume":"3","author":"Guillemont","year":"2011","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib130","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1016\/j.bmcl.2017.10.042","article-title":"Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units","volume":"27","author":"Choi","year":"2017","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2025.01.023_bib131","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1016\/j.bmc.2018.02.026","article-title":"Structure\u2012activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles","volume":"26","author":"Sutherland","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib132","doi-asserted-by":"crossref","first-page":"e02418","DOI":"10.1128\/AAC.02418-20","article-title":"Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis","volume":"65","author":"Xu","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib133","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01412-21","article-title":"Comparative efficacy of the novel diarylquinoline TBAJ-876 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis","volume":"65","author":"Almeida","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib134","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128824","article-title":"Discovery and preclinical profile of sudapyridine (WX-081), a novel anti-tuberculosis agent","volume":"71","author":"Huang","year":"2022","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2025.01.023_bib135","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.02477-21","article-title":"Sudapyridine (WX-081), a novel compound against Mycobacterium tuberculosis","volume":"10","author":"Yao","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.apsb.2025.01.023_bib136","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1039\/D1MD00063B","article-title":"Synthesis and evaluation of pyridine-derived bedaquiline analogues containing modifications at the A-ring subunit","volume":"12","author":"Barbaro","year":"2021","journal-title":"RSC Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib137","doi-asserted-by":"crossref","first-page":"5293","DOI":"10.1021\/jm5003606","article-title":"Lead optimization of a novel series of imidazo[1,2-a]pyridine amides leading to a clinical candidate (Q203) as a multi- and extensively-drug-resistant anti-tuberculosis agent","volume":"57","author":"Kang","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib138","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/nm.3262","article-title":"Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis","volume":"19","author":"Pethe","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2025.01.023_bib139","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0052951","article-title":"Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M. tuberculosis QcrB","volume":"7","author":"Abrahams","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2025.01.023_bib140","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ejmech.2016.09.082","article-title":"Synthesis and structure\u2012activity studies of side chain analogues of the anti-tubercular agent, Q203","volume":"125","author":"Kang","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib141","unstructured":"No Z, Kim J, Brodin PB, Seo MJ, Kim YM, Cechetto J, et\u00a0al, inventors. Anti-infective compounds. WO2011113606A1, September 22, 2011."},{"key":"10.1016\/j.apsb.2025.01.023_bib142","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1021\/acsmedchemlett.5b00176","article-title":"Design, synthesis, and biological evaluation of pyrazolo[1,5-a]pyridine-3-carboxamides as novel antitubercular agents","volume":"6","author":"Tang","year":"2015","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.apsb.2025.01.023_bib143","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227224","article-title":"Intracellular and in\u00a0vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds","volume":"15","author":"Moraski","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2025.01.023_bib144","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1021\/acsinfecdis.5b00154","article-title":"Arrival of imidazo[2,1-b]thiazole-5-carboxamides: potent anti-tuberculosis agents that target QcrB","volume":"2","author":"Moraski","year":"2016","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2025.01.023_bib145","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejmech.2016.09.030","article-title":"Pyrazolo[1,5-a]pyridine-3-carboxamide hybrids: design, synthesis and evaluation of anti-tubercular activity","volume":"125","author":"Lu","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib146","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1021\/acsinfecdis.8b00225","article-title":"Pyrazolo[1,5-a]pyridine inhibitor of the respiratory cytochrome bcc complex for the treatment of drug-resistant tuberculosis","volume":"5","author":"Lu","year":"2019","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2025.01.023_bib147","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s40793-015-0071-4","article-title":"Complete genome sequence of Mycobacterium tuberculosis K from a Korean high school outbreak, belonging to the Beijing family","volume":"10","author":"Han","year":"2015","journal-title":"Stand Genom Sci"},{"key":"10.1016\/j.apsb.2025.01.023_bib148","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TBTB2-0027-2016","article-title":"DNA replication in Mycobacterium tuberculosis","volume":"5","author":"Ditse","year":"2017","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.apsb.2025.01.023_bib149","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/s41467-017-00886-w","article-title":"High-fidelity DNA replication in Mycobacterium tuberculosis relies on a trinuclear zinc center","volume":"8","author":"Ba\u00f1os-Mateos","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.01.023_bib150","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.2165\/00003495-200767140-00007","article-title":"Fluoroquinolones for the treatment of pulmonary tuberculosis","volume":"67","author":"Moadebi","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.01.023_bib151","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02516-18","article-title":"Fluoroquinolone efficacy against tuberculosis is driven by penetration into lesions and activity against resident bacterial populations","volume":"63","author":"Sarathy","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib152","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1128\/AAC.04347-14","article-title":"A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections","volume":"59","author":"Locher","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib153","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01208-21","article-title":"First-in-human evaluation of the safety, tolerability, and pharmacokinetics of SPR720, a novel oral bacterial DNA gyrase (GyrB) inhibitor for mycobacterial infections","volume":"65","author":"Talley","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib154","doi-asserted-by":"crossref","first-page":"8792","DOI":"10.1021\/jm500563g","article-title":"Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability","volume":"57","author":"Grillot","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib155","doi-asserted-by":"crossref","first-page":"5243","DOI":"10.1021\/jm800318d","article-title":"Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: intelligent design and evolution through the judicious use of structure-guided design and structure\u2012activity relationships","volume":"51","author":"Charifson","year":"2008","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib156","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/AAC.00596-06","article-title":"Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds","volume":"51","author":"Grossman","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib157","doi-asserted-by":"crossref","first-page":"5185","DOI":"10.1128\/AAC.00699-11","article-title":"Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation","volume":"55","author":"Lu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib158","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/1791013a0","article-title":"A new series of phenazines (rimino-compounds) with high antituberculosis activity","volume":"179","author":"Barry","year":"1957","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.01.023_bib159","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/jac\/dkr444","article-title":"Clofazimine: current status and future prospects","volume":"67","author":"Cholo","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib160","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1164\/rccm.201001-0077OC","article-title":"Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis","volume":"182","author":"Van Deun","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2025.01.023_bib161","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jid.2017.09.031","article-title":"The physicochemical basis of clofazimine-induced skin pigmentation","volume":"138","author":"Murashov","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.apsb.2025.01.023_bib162","doi-asserted-by":"crossref","first-page":"8409","DOI":"10.1021\/jm300828h","article-title":"Identification of less lipophilic riminophenazine derivatives for the treatment of drug-resistant tuberculosis","volume":"55","author":"Zhang","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib163","doi-asserted-by":"crossref","first-page":"4545","DOI":"10.3390\/molecules17044545","article-title":"Systematic evaluation of structure\u2012activity relationships of the riminophenazine class and discovery of a C2 pyridylamino series for the treatment of multidrug-resistant tuberculosis","volume":"17","author":"Liu","year":"2012","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2025.01.023_bib164","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.3390\/molecules19044380","article-title":"Synthesis and biological evaluation of novel 2-methoxypyridylamino-substituted riminophenazine derivatives as antituberculosis agents","volume":"19","author":"Zhang","year":"2014","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2025.01.023_bib165","first-page":"1083","article-title":"Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis. In\u00a0vitro, intracellular, and in\u00a0vivo studies","volume":"151","author":"Jagannath","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.apsb.2025.01.023_bib166","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1128\/AAC.40.3.633","article-title":"Antituberculosis activities of clofazimine and its new analogs B4154 and B4157","volume":"40","author":"Reddy","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib167","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000007255","article-title":"In\u00a0vitro investigation of the antimicrobial activities of novel tetramethylpiperidine-substituted phenazines against Mycobacterium tuberculosis","volume":"46","author":"van Rensburg","year":"2000","journal-title":"Chemotherapy"},{"key":"10.1016\/j.apsb.2025.01.023_bib168","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1016\/j.bmcl.2005.01.085","article-title":"Antitubercular agents. part 1: synthesis of phthalimido- and naphthalimido-linked phenazines as new prototype antitubercular agents","volume":"15","author":"Kamal","year":"2005","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.apsb.2025.01.023_bib169","first-page":"745","article-title":"Synthesis and anti-tubercular activity of novel alkyl substituted riminophenazine derivatives","volume":"47","author":"Li","year":"2012","journal-title":"Yao Xue Xue Bao"},{"key":"10.1016\/j.apsb.2025.01.023_bib170","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00132-22","article-title":"GSK2556286 is a novel antitubercular drug candidate effective in\u00a0vivo with the potential to shorten tuberculosis treatment","volume":"66","author":"Nuermberger","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib171","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009862","article-title":"Pharmacological and genetic activation of cAMP synthesis disrupts cholesterol utilization in Mycobacterium tuberculosis","volume":"18","author":"Wilburn","year":"2022","journal-title":"Plos Pathog"},{"key":"10.1016\/j.apsb.2025.01.023_bib172","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01294-22","article-title":"Cyclic AMP-mediated inhibition of cholesterol catabolism in Mycobacterium tuberculosis by the novel drug candidate GSK2556286","volume":"67","author":"Brown","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib173","author":"Alemparte-Gallardo"},{"key":"10.1016\/j.apsb.2025.01.023_bib174","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.ijid.2021.02.067","article-title":"Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic","volume":"113","author":"Tiberi","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.apsb.2025.01.023_bib175","year":"2021","journal-title":"Glob tuberculosis Rep"},{"key":"10.1016\/j.apsb.2025.01.023_bib176","doi-asserted-by":"crossref","first-page":"e1323","DOI":"10.1016\/S2214-109X(23)00360-1","article-title":"What is the impact of the COVID-19 pandemic on tuberculosis?","volume":"11","author":"Kyu","year":"2023","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.apsb.2025.01.023_bib177","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1038\/s41467-021-24127-3","article-title":"Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide","volume":"12","author":"Santucci","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.01.023_bib178","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1128\/AAC.00217-12","article-title":"Evaluation of a mouse model of necrotic granuloma formation using C3HeB\/FeJ mice for testing of drugs against Mycobacterium tuberculosis","volume":"56","author":"Driver","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib179","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1128\/AAC.01423-09","article-title":"Fast standardized therapeutic-efficacy assay for drug discovery against tuberculosis","volume":"54","author":"Rullas","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib180","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.TBTB2-0034-2017","article-title":"Preclinical efficacy testing of new drug candidates","volume":"5","author":"Nuermberger","year":"2017","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.apsb.2025.01.023_bib181","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1021\/acsinfecdis.6b00051","article-title":"Prediction of drug penetration in tuberculosis lesions","volume":"2","author":"Sarathy","year":"2016","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.apsb.2025.01.023_bib182","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02266-17","article-title":"Extreme drug tolerance of Mycobacterium tuberculosis in caseum","volume":"62","author":"Sarathy","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.apsb.2025.01.023_bib183","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41429-019-0205-9","article-title":"Strategies in anti-Mycobacterium tuberculosis drug discovery based on phenotypic screening","volume":"72","author":"Grzelak","year":"2019","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.apsb.2025.01.023_bib184","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.addr.2016.04.026","article-title":"New agents for the treatment of drug-resistant Mycobacterium tuberculosis","volume":"102","author":"Hoagland","year":"2016","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.01.023_bib185","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/ncomms1060","article-title":"A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in\u00a0vivo efficacy","volume":"1","author":"Pethe","year":"2010","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.01.023_bib186","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.copbio.2017.03.023","article-title":"Novel and revisited approaches in antituberculosis drug discovery","volume":"48","author":"Herrmann","year":"2017","journal-title":"Curr Opin Biotechnol"},{"key":"10.1016\/j.apsb.2025.01.023_bib187","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2015.0506","article-title":"Inhibiting Mycobacterium tuberculosis within and without","volume":"371","author":"Cole","year":"2016","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"10.1016\/j.apsb.2025.01.023_bib188","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.4155\/fmc.10.223","article-title":"High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in\u00a0vitro model for tuberculosis drug discovery","volume":"2","author":"Christophe","year":"2010","journal-title":"Future Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib189","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112175","article-title":"Repurposed drug candidates for antituberculosis therapy","volume":"192","author":"An","year":"2020","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.apsb.2025.01.023_bib190","article-title":"\u201cUpcycling\u201d known molecules and targets for drug-resistant TB","volume":"12","author":"Roubert","year":"2022","journal-title":"Front Cel Infect Microbiol"},{"key":"10.1016\/j.apsb.2025.01.023_bib191","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1038\/ncomms8659","article-title":"Lansoprazole is an antituberculous prodrug targeting cytochrome Bc1","volume":"6","author":"Rybniker","year":"2015","journal-title":"Nat Commun"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T12:17:53Z","timestamp":1762604273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":187,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["S2211383525000292"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.01.023","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.01.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}